Kevin Pan – CEO, Asieris, China
Kevin Pan, CEO of Asieris, shares the origins behind the company’s distinctive name and how it reflects their ambition to bridge scientific discoveries and innovative medicines; their focus on genitourinary…
Asieris Pharmaceuticals, founded in March 2010 in China Medical City in Jiangsu Taizhou, is the only China-based, globally-oriented company specializing in the R&D of new drugs for the treatment of genitourinary tumours and related diseases.
Our professional teams are located in Shanghai, Beijing, and Taizhou (Jiangsu), as well as in the United States. With our focus on genitourinary tumours and related diseases, our goal is to establish a leading position in this field with our own unique strategies. Through the “twin engines” of proprietary R&D and in-licensing, we explore the global values of proprietary first-in-class new drugs of breakthrough potential. Meanwhile, we in-license late-stage or marketed new drugs from overseas for the Chinese market to enhance our product pipeline and allow us to quickly establish our leadership position in the domestic market.
Contact
12F, Building 56，No.1000 Jinhai Road, City of Elite, Pudong, Shanghai, China
Tel: +(86) 21 68585280
Kevin Pan, CEO of Asieris, shares the origins behind the company’s distinctive name and how it reflects their ambition to bridge scientific discoveries and innovative medicines; their focus on genitourinary…
In 2024, contract manufacturers WuXi Biologics and WuXi AppTec were catapulted into global consciousness as two of five Chinese service providers deemed a US national security threat in a draft…
This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Trinomab preparing for a STAR Market IPO to raise RMB 1.5 billion for its monoclonal antibody portfolio, including first-in-class…
Founded by Dr Helen Yang and Dr Peter He, Oricell Therapeutics stands at the forefront of next-generation cell and gene therapy innovation. Built on a comprehensive platform that integrates antibody…
Suzhou’s bioBAY has emerged as one of China’s most dynamic biotechnology clusters, bringing together hundreds of biotech and medtech companies within an ecosystem designed to support the full innovation cycle,…
Writing in the March 2026 edition of DIA’s Global Forum magazine, PharmCube’s Juan Valencia looks back on a record year for drug approvals in China, and what it means for…
Following our conversation with CEO Lance Yuen on CK Life Sciences’ strategic direction, Chief Scientific Officer Melvin Toh now takes us inside the scientific engine driving that vision forward. He…
Developing effective CAR-T therapies for T-cell malignancies remains one of the most technically challenging frontiers in cell therapy. Dr Lin Yang of PersonGen Biotherapeutics discusses the company’s progress with its…
From factory automation in Silicon Valley to scalable service robotics embedded in daily care, Roy Long Hei’s journey with Robocore reflects a disciplined belief that technology must prove itself in…
Hong Kong is quietly re-engineering how clinical research is organised and delivered across one of the world’s most dynamic life-sciences regions. Through the Greater Bay Area International Clinical Trial Institute…
China Biotech private financing in H2 2025 reflected a distinct “flight to quality,” moving from the valuation outliers of Q3 toward a disciplined clinical focus in Q4. As Dr Cathy…
Cancer drug development has produced an abundance of therapies, yet outcomes in solid tumours remain constrained by resistance and relapse. In this interview, Zaiqi Wang, Chairman and CEO of InxMed,…
Shaped by decades across US biotech, big pharma, and China’s high-intensity innovation environment, Dr Jing Li brings a rare end-to-end perspective on how biologics move from idea to impact. In…
See our Cookie Privacy Policy Here
